Abiraterone acetate (CB7630), a pregnenolone analog, is an orally administered small molecule that irreversibly inhibits a rate-limiting enzyme in androgen biosysnthesis, CYP17, and blocks the ...

Their hope was to use the drug to directly disrupt testosterone production, which fuels prostate cancer. The team initially developed a chemical called CB7598, which then became abiraterone acetate.

Recent years have seen the international standard of care for mHSPC evolve to include androgen-deprivation therapy combined ...

Truqap combination showed a statistically and clinically meaningful improvement in radiographic progression-free survival for ...

Capivasertib combination shows promise in mHSPC vs the placebo combination, LBS-007 received fast track designation, and RP1 plus nivolumab submitted a BLA application. We also cover a retrospective ...

In the ENZ group, six patients received further treatments after AA progression: four ENZ, one cabazitaxel and another docetaxel followed by abiraterone. Among the 30 patients showing a ...

Abiraterone acetate is a type of hormone therapy for men with prostate cancer that has spread to other parts of the body and is usually only offered to men whose cancer has stopped responding to ...

Abiraterone is one of the ICR’s biggest success stories – the first treatment shown to be effective in men with advanced prostate cancer. In 2012 it was made available on the NHS, at a stroke ...

Giles Turner, from Sussex, is paying for abiraterone privately at a cost of £250 per month Thousands of patients in England and Northern Ireland are missing out on a life-extending prostate ...

The EMA’s human medicines committee has recommended approval for Akeega, a fixed-dose combination of J&J’s PARP drug Zejula (niraparib) and androgen inhibitor Zytiga (abiraterone acetate), in ...

Dr. Scott Tagawa presented ProstACT GLOBAL, a phase III study of best SOC with or without 177 Lu-DOTA-rosopatamab (TLX591) for patients with PSMA-expressing mCRPC who experienced disease progression ...